Zobrazeno 1 - 10
of 334
pro vyhledávání: '"MITSUHIRO TAKENOYAMA"'
Autor:
Mototsugu Shimokawa, Masaki Kanazu, Ryusei Saito, Masahide Mori, Atsuhisa Tamura, Yoshio Okano, Yuka Fujita, Takeo Endo, Mitsuru Motegi, Shohei Takata, Toshiyuki Kita, Noriaki Sukoh, Fumitaka Mizuki, Mitsuhiro Takenoyama, Shinji Atagi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 17, Pp 1597-1605 (2023)
Abstract Background Previous trials suggest that older adults with non‐small cell lung cancer (NSCLC) derive benefit from platinum doublet combination therapy, but its superiority is controversial. Although geriatric assessment variables are used t
Externí odkaz:
https://doaj.org/article/76404a9fd6d2454e84c0f25fef6834a6
Autor:
Yasuto Yoneshima, Eiji Iwama, Shingo Matsumoto, Taichi Matsubara, Testuzo Tagawa, Keiichi Ota, Kentaro Tanaka, Mitsuhiro Takenoyama, Tatsuro Okamoto, Koichi Goto, Masaki Mori, Isamu Okamoto
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Genetic alterations underlying the development of lung cancer in individuals with idiopathic pulmonary fibrosis (IPF) have remained unclear. To explore whether genetic alterations in IPF tissue contribute to the development of IPF-associated
Externí odkaz:
https://doaj.org/article/9cdaf15acea343ac89678c3375dbc507
Autor:
Tomoshi Tsuchiya, Ryotaro Kamohara, Masashi Muraoka, Takeshi Nagayasu, Sho Saeki, Mitsuhiro Takenoyama, Makoto Suzuki, Kazuo Inada, Shoji Tokunaga, Tomayoshi Hayashi, Shogo Urabe, Takaomi Koga, Shinji Akamine, Kenji Sugio
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Lymphovascular invasion (LVI), which includes vascular or lymphatic invasions, is a representative prognostic factor even in patients with resected stage IA non-small cell lung cancer (NSCLC). Because tegafur-uracil is effective o
Externí odkaz:
https://doaj.org/article/6f5c1773999b475b844c5c01eaf8e53c
Autor:
Akihiro Tamiya, Yasuhiro Koh, Shun‐ichi Isa, Akihito Kubo, Masahiko Ando, Hideo Saka, Naoki Yoshimoto, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Mitsuhiro Takenoyama, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Tomoya Kawaguchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 7, Pp 2343-2351 (2020)
Abstract Background To report the follow up data and clinical outcomes of the JME study (UMIN 000008177), a prospective, multicenter, molecular epidemiology examination of 876 surgically resected non‐small‐cell lung cancer (NSCLC) cases, and the
Externí odkaz:
https://doaj.org/article/5683b6fa5c354da5939ae03f12b109d8
Autor:
Minoru Fukuda, Soichiro Funaki, Takuya Yamazaki, Shuntaro Sato, Hiroshi Mukae, Mitsuhiro Takenoyama, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio
Publikováno v:
Thoracic Cancer, Vol 11, Iss 3, Pp 693-696 (2020)
Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S‐1 treatment is effective against thymic carcinoma. S‐1
Externí odkaz:
https://doaj.org/article/031b35c58f8145759793fa77ecb548c0
Autor:
Kazuhiko Nakagawa, MD, PhD, Takashi Kijima, MD, PhD, Morihito Okada, MD, PhD, Masahiro Morise, MD, PhD, Motoyasu Kato, MD, PhD, Katsuya Hirano, MD, Nobukazu Fujimoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Hiroshi Yokouchi, MD, PhD, Yuichiro Ohe, MD, PhD, Toyoaki Hida, MD, PhD, Keisuke Aoe, MD, PhD, Takumi Kishimoto, MD, PhD, Masato Hirokawa, MSc, Hironori Matsuki, MEng, Yutaro Kaneko, BSc, Taketo Yamada, MD, PhD, Chikao Morimoto, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100178- (2021)
Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesoth
Externí odkaz:
https://doaj.org/article/e0dd33bf32bd4e94a6baf9946819d8b9
Autor:
Shinkichi Takamori, Takashi Seto, Mikako Jinnouchi, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Mitsuhiro Takenoyama
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 2056-2058 (2020)
In patients with non‐small cell lung cancer (NSCLC), stereotactic radiotherapy (SRT) is one of the standard therapies for those suffering with intracranial metastatic NSCLC. Radiation‐induced necrosis (RIN) sometimes occurs as the result of the d
Externí odkaz:
https://doaj.org/article/75e151e3e4c74195b8423bd23b104805
Autor:
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Abstract Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients wi
Externí odkaz:
https://doaj.org/article/98ef3513e3d64aad8fdc1d5b550e05c4
Autor:
Naoki Haratake, Takashi Seto, Shinkichi Takamori, Ryo Toyozawa, Kaname Nosaki, Naoko Miura, Taro Ohba, Gouji Toyokawa, Kenichi Taguchi, Masafumi Yamaguchi, Mototsugu Shimokawa, Mitsuhiro Takenoyama
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1779-1787 (2019)
Background Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for s
Externí odkaz:
https://doaj.org/article/ace1fff5d8aa4be1bb629186648528c3
Autor:
Shinkichi Takamori, Taro Ohba, Mototsugu Shimokawa, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama
Publikováno v:
PLoS ONE, Vol 16, Iss 10 (2021)
Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have markedly improved the prognosis of many patients with advanced non-small cell lung cancer (NSCLC). However, the relationship
Externí odkaz:
https://doaj.org/article/912f46bb1a0349f194025e3274903265